15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Beam Therapeutics Inc, 8 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $26.00 to $80.00 (about 3.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $50.80 sits 89% above the current $26.83. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 8 over recent months. On the fundamentals, the Street sees revenue growth near -47% this year and 28% next, consensus EPS building from about $-1.19 next quarter toward $-4.74 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Strong Buy
Strong Buy00%
Buy880%
Hold220%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Beam Therapeutics Inc.
As of Sep, 8 of 10 firms rate BEAM a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BEAM EPS & revenue forecast
EPS · NEXT QUARTER
$-1.19
Range $-1.34 – $-1.06 · 13 analysts · -151% YoY
Next period, 13 analysts expect Beam Therapeutics Inc to earn $-1.19 a share (range $-1.34 – $-1.06), versus $2.33 a year earlier. Full-year consensus is $-4.45, growing to $-4.74 the year after.
REVENUE · NEXT QUARTER
$11.6M
Range $500.0K – $32.2M · 13 analysts · +78% YoY
Revenue is expected to reach $11.6M (range $500.0K – $32.2M), +78.0% year-over-year. Full-year consensus is $48.6M, rising to $62.7M next year.
Top analysts covering Beam Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BEAM.
#1
Luca Issi
RBC Capital · Rank #1
Hold
$26.00-3.1% to target
Overall win rate
55%
+ Follow
#2
David Nierengarten
Wedbush · Rank #66
Buy
$65.00+142.3% to target
Overall win rate
42%
+ Follow
#3
Debjit Chattopadhyay
Guggenheim · Rank #113
Buy
$55.00+105.0% to target
Overall win rate
44%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #179
Buy
$40.00+49.1% to target
Overall win rate
38%
+ Follow
#5
Patrick R. Trucchio
HC Wainwright & Co. · Rank #230
Buy
$80.00+198.2% to target
Overall win rate
36%
+ Follow
BEAM stock forecast FAQ
What is BEAM's average 12-month price target?+
The 10 analysts with a live target average $50.80 for Beam Therapeutics Inc over the next 12 months, ranging from a $80.00 high to a $26.00 low.
Is BEAM stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 10 analyst ratings, 8 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BEAM?+
The Street-high target is $80.00 (HC Wainwright & Co.), and the Street-low is $26.00 (RBC Capital). The average of all 10 active targets is $50.80.
How many Wall Street analysts cover BEAM?+
10 analysts have an active rating on Beam Therapeutics Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering BEAM?+
Among analysts who currently cover BEAM, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #1). Their current call is Hold with a $26.00 target.
What is Beam Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.19 per share (range $-1.34 – $-1.06) across 13 analysts. Full-year EPS is projected at $-4.45, rising to $-4.74 the following year.
How much revenue is Beam Therapeutics Inc expected to report next quarter?+
Consensus revenue is $11.6M (range $500.0K – $32.2M). Full-year revenue is projected at $48.6M, growing to $62.7M next year.
Have analysts been upgrading or downgrading BEAM lately?+
As of Sep, 8 of 10 firms rate BEAM a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BEAM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
